AR088510A1 - Moduladores de trpv3 - Google Patents

Moduladores de trpv3

Info

Publication number
AR088510A1
AR088510A1 ARP120103975A ARP120103975A AR088510A1 AR 088510 A1 AR088510 A1 AR 088510A1 AR P120103975 A ARP120103975 A AR P120103975A AR P120103975 A ARP120103975 A AR P120103975A AR 088510 A1 AR088510 A1 AR 088510A1
Authority
AR
Argentina
Prior art keywords
cr1ar1b
alkyl
haloalkyl
independently
halogen
Prior art date
Application number
ARP120103975A
Other languages
English (en)
Inventor
G Schmidt Robert
J Dart Michael
Gfesser Gregory
K Bayburt Erol
Clapham Bruce
B Cox Phil
F Daanen Jerome
Gomtsyan Arthur
E Kort Michael
R Kym Philip
A Voight Eric
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of AR088510A1 publication Critical patent/AR088510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Channel Selection Circuits, Automatic Tuning Circuits (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Steroid Compounds (AREA)

Abstract

Además, composiciones que comprenden dichos compuestos y métodos para el tratamiento de condiciones y trastornos usando dichos compuestos y composiciones. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o una sal del mismo, donde: las instancias de Rᵃ y Rᵇ son en forma independiente entre sí hidrógeno, alquilo, haloalquilo, halógeno, OH, O(alquilo), o un grupo fenilo que está opcionalmente sustituido con 1, 2, 3, 4, ó 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, haloalquilo, y halógeno; u es 0, 1, ó 2; X³ es CH₂; X⁴ es (CH₂)ₘ; X⁵ es (CH₂)ₙ; m y n son cada uno 1; cada grupo Z¹ es un sustituyente sobre cualquier átomo de carbono del anillo que pueda estar sustituido que contiene X³, X⁴, y X⁵, y es en forma independiente alquilo, C(O)Rᶜᶻ, S(O)₂Rᶜᶻ, N(R¹ᵈ)(R²ᵈ), ORᶜ, oxo, =NORᶻ¹, =NNRᶻ¹Rᶻ², =NRᶻ³, halógeno, haloalquilo, -(alquilenil C₁₋₆)ORᶜ, -(alquilenil C₁₋₆)-C(O)Rᶜᶻ, -(alquilenil C₁₋₆)S(O)₂Rᶜᶻ, o -(alquilenil C₁₋₆)-N(R¹ᵈ)(R²ᵈ); dos grupos Z¹ que se sitúan en el mismo átomo de carbono, junto con el átomo de carbono al cual se encuentran unidos forman opcionalmente un anillo cicloalquilo monocíclico o heterociclo monocíclico de 4 - 6 miembros; donde dicho anillo está opcionalmente sustituido con 1, 2, 3, ó 4 sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, haloalquilo, y halógeno; Rᶻ¹, Rᶻ², Rᶻ³ son en forma independiente entre sí hidrógeno, alquilo, -C(O)(alquilo), -C(O)-Gᵈ, o haloalquilo; Rᶜᶻ, en cada caso, es en forma independiente alquilo, haloalquilo, NH₂, N(H)(alquilo), o N(alquilo)₂; R¹ᵈ, en cada caso, es en forma independiente hidrógeno, alquilo, haloalquilo, C(O)alquilo, o C(O)O(alquilo); R²ᵈ y Rᶜ, en cada caso, son en forma independiente entre sí hidrógeno, alquilo, o haloalquilo; p es 1, 2, 3, ó 4; X¹ es -OH y X² es hidrógeno; G¹ es arilo, heteroarilo, cicloalquilo, heterociclo, o cicloalquenilo; cada uno de los cuales está opcionalmente sustituido con 1, 2, 3, 4, ó 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, halógeno, haloalquilo, ORᵍᶜ, N(Rᵍᶜ)₂, N(Rᵍᶜ)C(O)alquilo, heteroarilo, y heterociclo; las unidades heteroarilo y heterociclo en forma independiente entre sí no están sustituidas o están sustituidas con 1, 2, 3, 4, ó 5 sustituyentes seleccionados entre el grupo que consiste en alquilo, O(alquilo), halógeno, y haloalquilo; y donde cada Rᵍᶜ es en forma independiente hidrógeno, alquilo, o haloalquilo; G² es G²ᵈ o -(CR¹ᵍR²ᵍ)ʳ-G²ᵈ donde: r es 1, 2, ó 3; R¹ᵍ y R²ᵍ son iguales o diferentes, y son en forma independiente entre sí hidrógeno, alquilo, halógeno, OR¹ᵍᶜ, N(R¹ᵍᶜ)₂, C(O)alquilo, o haloalquilo; donde cada R¹ᵍᶜ es en forma independiente hidrógeno, alquilo, o haloalquilo; G²ᵈ es arilo, heteroarilo, cicloalquilo, heterociclo, o cicloalquenilo, cada uno de los cuales está opcionalmente sustituido con 1, 2, 3, 4, ó 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en Gᵈ, alquilo, alquenilo, alquinilo, halógeno, haloalquilo, -CN, -ORᶠ, -OC(O)Rᶠ, -OC(O)N(Rᶠ)₂, -S(O)₂Rᵉ, -S(O)₂N(Rᶠ)₂, -C(O)Rᶠ, -C(O)ORᶠ, -C(O)N(Rᶠ)₂, -N(Rᶠ)₂, -N(Rᶠ)C(O)Rᶠ, -N(Rᶠ)S(O)₂Rᵉ, -N(Rᶠ)C(O)O(Rᵉ), -N(Rᶠ)C(O)N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-Gᵈ, -(CR¹ᵃR¹ᵇ)q-ORᶠ, -(CR¹ᵃR¹ᵇ)q-OC(O)Rᶠ, -(CR¹ᵃR¹ᵇ)q-OC(O)N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-S(O)₂Rᵉ, -(CR¹ᵃR¹ᵇ)q-S(O)₂N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-C(O)Rᶠ, -(CR¹ᵃR¹ᵇ)q-C(O)ORᶠ, -(CR¹ᵃR¹ᵇ)q-C(O)N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)₂, -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)C(O)Rᶠ, -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)S(O)₂Rᵉ, -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)C(O)O(Rᵉ), -(CR¹ᵃR¹ᵇ)q-N(Rᶠ)C(O)N(Rᶠ)₂, y -(CR¹ᵃR¹ᵇ)q-CN; R¹ᵃ y R¹ᵇ, son iguales o diferentes, y en cada caso son en forma independiente entre sí hidrógeno, halógeno, alquilo, o haloalquilo; cada instancia de Rᶠ es en forma independiente hidrógeno, alquilo, haloalquilo, Gᵈ, o -(CR¹ᵃR¹ᵇ)q-Gᵈ; cada instancia de Rᵉ es en forma independiente alquilo, haloalquilo, Gᵈ, o -(CR¹ᵃR¹ᵇ)q-Gᵈ; q, en cada caso, es en forma independiente 1, 2, ó 3; cada instancia de Gᵈ es en forma independiente arilo, heteroarilo, cicloalquilo, heterociclo, o cicloalquenilo; y está opcionalmente sustituido en cada caso con 1, 2, 3, 4, o 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, halógeno, haloalquilo, -CN, -ORʲ, -OC(O)Rʲ, -OC(O)N(Rʲ)₂, -S(O)₂Rᵏ, -S(O)₂N(Rʲ)₂, -C(O)Rʲ, -C(O)ORʲ, -C(O)N(Rʲ)₂, -N(Rʲ)₂, -N(Rʲ)C(O)Rʲ, -N(Rʲ)S(O)₂Rᵏ, -N(Rʲ)C(O)O(Rᵏ), -N(Rʲ)C(O)N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-ORʲ, -(CR¹ᵃR¹ᵇ)q-OC(O)Rʲ, -(CR¹ᵃR¹ᵇ)q-OC(O)N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-S(O)₂Rᵏ, -(CR¹ᵃR¹ᵇ)q-S(O)₂N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-C(O)Rʲ, -(CR¹ᵃR¹ᵇ)q-C(O)ORʲ, -(CR¹ᵃR¹ᵇ)q-C(O)N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-N(Rʲ)₂, -(CR¹ᵃR¹ᵇ)q-N(Rʲ)C(O)Rʲ, -(CR¹ᵃR¹ᵇ)q-N(Rʲ)S(O)₂Rᵏ, -(CR¹ᵃR¹ᵇ)q-N(Rʲ)C(O)O(Rᵏ), -(CR¹ᵃR¹ᵇ)q-N(Rʲ)C(O)N(Rʲ)₂, y (CR¹ᵃR¹ᵇ)q-CN; cada instancia de Rʲ es en forma independiente hidrógeno, alquilo, o haloalquilo; y cada instancia de Rᵏ es en forma independiente alquilo o haloalquilo.
ARP120103975A 2011-10-24 2012-10-24 Moduladores de trpv3 AR088510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011001761 2011-10-24

Publications (1)

Publication Number Publication Date
AR088510A1 true AR088510A1 (es) 2014-06-18

Family

ID=47178922

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120103976A AR088511A1 (es) 2011-10-24 2012-10-24 Derivados heterociclicos como moduladores de trpv3
ARP120103975A AR088510A1 (es) 2011-10-24 2012-10-24 Moduladores de trpv3

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120103976A AR088511A1 (es) 2011-10-24 2012-10-24 Derivados heterociclicos como moduladores de trpv3

Country Status (9)

Country Link
US (2) US8772500B2 (es)
EP (1) EP2771322A2 (es)
JP (1) JP2014530911A (es)
AR (2) AR088511A1 (es)
CA (1) CA2853097A1 (es)
MX (1) MX2014004979A (es)
TW (2) TW201323381A (es)
UY (2) UY34408A (es)
WO (2) WO2013062964A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013110324A (ru) 2010-08-10 2014-09-20 Эббви Инк. Новые модуляторы trpv3
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
MX2014004979A (es) 2011-10-24 2014-10-24 Abbvie Inc Derivados de metanol como moduladores de trpv3.
EP3262021B1 (en) * 2015-02-27 2021-06-30 The Feinstein Institute for Medical Research Treatment method, compounds, and method of increasing trpv2 activity
CN110382466B (zh) 2017-03-13 2023-01-31 拉夸里亚创药株式会社 作为p2x7受体拮抗剂的四氢喹啉衍生物
WO2024049929A2 (en) * 2022-08-30 2024-03-07 Pannex Therapeutics Inc. Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914820A1 (de) 1989-05-05 1990-11-08 Basf Ag Neue pyridinderivate und ihre verwendung als fungizide
DE4318916A1 (de) 1993-06-07 1994-12-08 Bayer Ag Cyclobutylazole
GB9315808D0 (en) 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
JP2002502844A (ja) 1998-02-03 2002-01-29 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト ５員複素環縮合ベンゾ誘導体、その調製及び医薬品としてのそれらの使用
US6114532A (en) 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
AU9087301A (en) * 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
CA2450113A1 (en) 2001-06-13 2002-12-19 Novartis Ag Vanilloid receptor-related nucleic acids and polypeptides
US7282591B2 (en) 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ZA200503654B (en) 2002-11-06 2006-09-27 Amgen Inc Fused heterocyclic compounds
EP1737850B1 (en) 2004-04-19 2007-10-03 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
CA2608194A1 (en) 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
TWI409070B (zh) 2005-11-04 2013-09-21 Hydra Biosciences Inc 用於調節ｔｒｐｖ３功能之化合物
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
CN101616902B (zh) 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
EP2217548A1 (en) 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
CA2728405A1 (en) 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Chromane derivatives as trpv3 modulators
US8501778B2 (en) * 2008-06-20 2013-08-06 Nhwa Pharma. Corporation Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent
US8318928B2 (en) 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
RU2579114C9 (ru) 2010-07-12 2016-05-27 Ф. Хоффманн-Ля Рош Аг 1-гидроксиимино-3-фенил-пропаны
RU2013110324A (ru) * 2010-08-10 2014-09-20 Эббви Инк. Новые модуляторы trpv3
MX2014004979A (es) 2011-10-24 2014-10-24 Abbvie Inc Derivados de metanol como moduladores de trpv3.

Also Published As

Publication number Publication date
US8772500B2 (en) 2014-07-08
US20140080803A1 (en) 2014-03-20
WO2013062966A3 (en) 2013-08-22
US8772499B2 (en) 2014-07-08
US20130131036A1 (en) 2013-05-23
CA2853097A1 (en) 2013-05-02
TW201323408A (zh) 2013-06-16
WO2013062964A3 (en) 2013-08-15
WO2013062966A2 (en) 2013-05-02
AR088511A1 (es) 2014-06-18
WO2013062964A2 (en) 2013-05-02
MX2014004979A (es) 2014-10-24
JP2014530911A (ja) 2014-11-20
UY34407A (es) 2013-05-31
UY34408A (es) 2013-05-31
TW201323381A (zh) 2013-06-16
EP2771322A2 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
AR088510A1 (es) Moduladores de trpv3
AR091023A1 (es) Inhibidores del nampt
AR089527A1 (es) Inhibidores de bromodominios
ES2722048T3 (es) Compuestos de triazolopirimidina y usos de los mismos
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
AR091022A1 (es) Inhibidores del nampt
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR106595A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR098912A1 (es) Inhibidores de syk
AR083946A1 (es) Metodos de tratamiento con inhibidores selectivos de bcl-2
AR088000A1 (es) Derivados de pirazolquinolinona, su preparacion y su uso terapeutico
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR087311A1 (es) Quinolinas sustituidas y su uso como medicamentos
AR086829A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR083694A1 (es) USO DE COMPUESTOS FARMACEUTICOS ACTIVOS PARA EL TRATAMIENTO DE ESTADOS PATOLOGICOS DEL SISTEMA NERVIOSO CENTRAL, COMPOSICION FARMACEUTICA, MODULADOR ALOSTERICO NEGATIVO DEL GABA A a5, METODO
AR104306A1 (es) Tetralinas de ácido 3-espiro-7-hidroxámico como inhibidores de hdac
AR093143A1 (es) Compuestos de 2-aminopiridina
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR088320A1 (es) Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR089814A1 (es) Compuestos que modulan la actividad de los proteasomas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal